Literature DB >> 34097899

Spontaneously Hypertensive Rat substrains show differences in model traits for addiction risk and cocaine self-administration: Implications for a novel rat reduced complexity cross.

Kathleen M Kantak1, Carissa Stots2, Elon Mathieson2, Camron D Bryant3.   

Abstract

Forward genetic mapping of F2 crosses between closely related substrains of inbred rodents - referred to as a reduced complexity cross (RCC) - is a relatively new strategy for accelerating the pace of gene discovery for complex traits, such as drug addiction. RCCs to date were generated in mice, but rats are thought to be optimal for addiction genetic studies. Based on past literature, one inbred Spontaneously Hypertensive Rat substrain, SHR/NCrl, is predicted to exhibit a distinct behavioral profile as it relates to cocaine self-administration traits relative to another substrain, SHR/NHsd. Direct substrain comparisons are a necessary first step before implementing an RCC. We evaluated model traits for cocaine addiction risk and cocaine self-administration behaviors using a longitudinal within-subjects design. Impulsive-like and compulsive-like traits were greater in SHR/NCrl than SHR/NHsd, as were reactivity to sucrose reward, sensitivity to acute psychostimulant effects of cocaine, and cocaine use studied under fixed-ratio and tandem schedules of cocaine self-administration. Compulsive-like behavior correlated with the acute psychostimulant effects of cocaine, which in turn correlated with cocaine taking under the tandem schedule. Compulsive-like behavior also was the best predictor of cocaine seeking responses. Heritability estimates indicated that 22 %-40 % of the variances for the above phenotypes can be explained by additive genetic factors, providing sufficient genetic variance to conduct genetic mapping in F2 crosses of SHR/NCrl and SHR/NHsd. These results provide compelling support for using an RCC approach in SHR substrains to uncover candidate genes and variants that are of relevance to cocaine use disorders.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Addiction vulnerability traits; Cocaine; SHR/NCrl substrain; SHR/NHsd substrain

Mesh:

Substances:

Year:  2021        PMID: 34097899      PMCID: PMC8265396          DOI: 10.1016/j.bbr.2021.113406

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.352


  86 in total

1.  Decreased motivation following cocaine self-administration under extended access conditions: effects of sex and ovarian hormones.

Authors:  Wendy J Lynch; Jane R Taylor
Journal:  Neuropsychopharmacology       Date:  2005-05       Impact factor: 7.853

Review 2.  Genetics of hypertension: an assessment of progress in the spontaneously hypertensive rat.

Authors:  Peter A Doris
Journal:  Physiol Genomics       Date:  2017-09-15       Impact factor: 3.107

3.  Comparing the utility of homogeneous subtypes of cocaine use and related behaviors with DSM-IV cocaine dependence as traits for genetic association analysis.

Authors:  Jinbo Bi; Joel Gelernter; Jiangwen Sun; Henry R Kranzler
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2013-12-11       Impact factor: 3.568

Review 4.  Breaking barriers in the genomics and pharmacogenetics of drug addiction.

Authors:  M K Ho; D Goldman; A Heinz; J Kaprio; M J Kreek; M D Li; M R Munafò; R F Tyndale
Journal:  Clin Pharmacol Ther       Date:  2010-10-27       Impact factor: 6.875

5.  Factors that determine a propensity for cocaine-seeking behavior during abstinence in rats.

Authors:  M A Sutton; D A Karanian; D W Self
Journal:  Neuropsychopharmacology       Date:  2000-06       Impact factor: 7.853

6.  Impulsivity predicts the escalation of cocaine self-administration in rats.

Authors:  Justin J Anker; Jennifer L Perry; Luke A Gliddon; Marilyn E Carroll
Journal:  Pharmacol Biochem Behav       Date:  2009-05-31       Impact factor: 3.533

7.  Genetic architecture of Wistar-Kyoto rat and spontaneously hypertensive rat substrains from different sources.

Authors:  Yanli Zhang-James; Frank A Middleton; Stephen V Faraone
Journal:  Physiol Genomics       Date:  2013-05-14       Impact factor: 3.107

8.  Adolescent d-amphetamine treatment in a rodent model of attention deficit/hyperactivity disorder: impact on cocaine abuse vulnerability in adulthood.

Authors:  Chloe J Jordan; Carley Lemay; Linda P Dwoskin; Kathleen M Kantak
Journal:  Psychopharmacology (Berl)       Date:  2016-09-06       Impact factor: 4.530

9.  Genomic landscape of rat strain and substrain variation.

Authors:  Roel Hermsen; Joep de Ligt; Wim Spee; Francis Blokzijl; Sebastian Schäfer; Eleonora Adami; Sander Boymans; Stephen Flink; Ruben van Boxtel; Robin H van der Weide; Tim Aitman; Norbert Hübner; Marieke Simonis; Boris Tabakoff; Victor Guryev; Edwin Cuppen
Journal:  BMC Genomics       Date:  2015-05-06       Impact factor: 3.969

10.  Ventral striatal regulation of CREM mediates impulsive action and drug addiction vulnerability.

Authors:  M L Miller; Y Ren; H Szutorisz; N A Warren; C Tessereau; G Egervari; A Mlodnicka; M Kapoor; B Chaarani; C V Morris; G Schumann; H Garavan; A M Goate; M J Bannon; J M Halperin; Y L Hurd
Journal:  Mol Psychiatry       Date:  2017-04-25       Impact factor: 15.992

View more
  3 in total

1.  Sex and heredity are determinants of drug intake in a novel model of rat oral oxycodone self-administration.

Authors:  Burt M Sharp; Xinyu Fan; Eva E Redei; Megan K Mulligan; Hao Chen
Journal:  Genes Brain Behav       Date:  2021-09-16       Impact factor: 3.449

Review 2.  Identification of the Risk Genes Associated With Vulnerability to Addiction: Major Findings From Transgenic Animals.

Authors:  Chloe J Jordan; Zheng-Xiong Xi
Journal:  Front Neurosci       Date:  2022-01-12       Impact factor: 4.677

3.  Role of preexisting inhibitory control deficits vs. drug use history in mediating insensitivity to aversive consequences in a rat model of polysubstance use.

Authors:  Elon Mathieson; Carolyn Irving; Sarah Koberna; Megan Nicholson; Michael W Otto; Kathleen M Kantak
Journal:  Psychopharmacology (Berl)       Date:  2022-04-07       Impact factor: 4.415

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.